Petros Grivas outlines the latest analyses of the JAVELIN Bladder 100 study of maintenance avelumab in metastatic urothelial cancer, including the assessment of efficacy by clinical and molecular subgroups and by the post-chemotherapy treatment-free interval, as well as data on time to end of subsequent therapy (6:30).
00:00 - JAVELIN Bladder 100 overview
01:15 - Efficacy by subgroups
02:37 - Efficacy by treatment-free interval
03:58 - Time to end of next-line therapy
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany